
A
Study
Experimental Events Total
Control Events Total
Risk Ratio
RR 95%−CI Weight
5mg 12weeks in plaque psoriasis
NCT00678210 3 49 0 50 7.14 [0.38; 134.70] 1.7%
5mg 16weeks in plaque psoriasis
NCT01276639 25 363 5 177 2.44 [0.95; 6.26] 22.6%
NCT01309737 16 382 6 196 1.37 [0.54; 3.44] 26.6%
Common effect model 745 373 1.86 [0.97; 3.58] 49.2%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.39
10mg 16weeks in plaque psoriasis
NCT01276639 24 360 5 177 2.36 [0.92; 6.08] 22.5%
NCT01309737 18 381 6 196 1.54 [0.62; 3.83] 26.6%
Common effect model 741 373 1.92 [1.00; 3.68] 49.1%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.53
Common effect model 1535 796 1.98 [1.25; 3.11] 100.0%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.75
Test for subgroup differences: $\chi^2_2$ = 0.77, df = 2 ($p$ = 0.68)
0.01 0.1 1 10 100
5mg 12weeks in psoriatic arthritis
NCT01882439 5 131 7 131 0.71 [0.23; 2.19] 31.8%
NCT01877668 4 107 4 105 0.98 [0.25; 3.82] 18.3%
Common effect model 238 236 0.81 [0.34; 1.92] 50.1%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.72
10mg 12weeks in psoriatic arthritis
NCT01882439 10 132 7 131 1.42 [0.56; 3.61] 31.9%
NCT01877668 10 104 4 105 2.52 [0.82; 7.79] 18.1%
Common effect model 236 236 1.82 [0.89; 3.71] 49.9%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.44
Common effect model 474 472 1.31 [0.77; 2.25] 100.0%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.45
Test for subgroup differences: $\chi^2_1$ = 1.99, df = 1 ($p$ = 0.16)
0.2 0.5 1 2 5
B
5mg 12weeks in plaque psoriasis
NCT00678210 1 49 5 50 0.20 [0.02; 1.68] 2.7%
NCT01241591 21 329 10 107 0.68 [0.33; 1.40] 12.7%
Random effects model 378 157 0.57 [0.25; 1.33] 15.4%
Heterogeneity: $I^2$ = 11%, $\hat{\tau}^2$ = 0.0822, $p$ = 0.29
10mg 12weeks in plaque psoriasis
NCT01241591 30 330 10 107 0.97 [0.49; 1.92] 13.4%
5mg 16weeks in plaque psoriasis
NCT01276639 20 363 20 177 0.49 [0.27; 0.88] 15.1%
NCT01309737 32 382 11 196 1.49 [0.77; 2.90] 13.7%
NCT01815424 8 88 3 88 2.67 [0.73; 9.72] 6.1%
Random effects model 833 461 1.12 [0.43; 2.95] 34.9%
Heterogeneity: $I^2$ = 78%, $\hat{\tau}^2$ = 0.5421, $p$ = 0.01
10mg 16weeks in plaque psoriasis
NCT01276639 31 360 20 177 0.76 [0.45; 1.30] 16.3%
NCT01309737 30 381 11 196 1.40 [0.72; 2.74] 13.6%
NCT01815424 9 90 3 88 2.93 [0.82; 10.48] 6.3%
Random effects model 831 461 1.24 [0.63; 2.41] 36.2%
Heterogeneity: $I^2$ = 57%, $\hat{\tau}^2$ = 0.1914, $p$ = 0.10
Random effects model 2372 1186 0.98 [0.68; 1.42] 100.0%
Heterogeneity: $I^2$ = 53%, $\hat{\tau}^2$ = 0.1442, $p$ = 0.03
Test for subgroup differences: $\chi^2_3$ = 2.12, df = 3 ($p$ = 0.55)
0.1 0.5 1 2 10
5mg 12weeks in psoriatic arthritis
NCT01882439 10 131 3 131 3.33 [0.94; 11.84] 24.9%
NCT01877668 4 107 3 105 1.31 [0.30; 5.71] 25.2%
Common effect model 238 236 2.32 [0.91; 5.92] 50.1%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.35
10mg 12weeks in psoriatic arthritis
NCT01882439 7 132 3 131 2.32 [0.61; 8.76] 25.0%
NCT01877668 6 104 3 105 2.02 [0.52; 7.86] 24.8%
Common effect model 236 236 2.17 [0.84; 5.61] 49.9%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.89
Common effect model 474 472 2.24 [1.15; 4.37] 100.0%
Heterogeneity: $I^2$ = 0%, $\hat{\tau}^2$ = 0, $p$ = 0.82
Test for subgroup differences: $\chi^2_1$ = 0.01, df = 1 ($p$ = 0.92)
0.1 0.5 1 2 10

**Figure S8** Forest plot of tofacitinib treatment for Safety indicators in each clinical manifestation of psoriatic disease. **A**: Safety analysis of tofacitinib compared with placebo by different treatment plans for Headache. **B**: Safety analysis of tofacitinib compared with placebo by different treatment plans for Nasopharyngitis.